study for patients with locally advanced rectal cancer given neoadjuvant chemoradiotherapy were approved by the Institutional Review Board and the Regional Committee for Medical and Health Research Ethics South-East Norway, and were performed in accordance with the Declaration of Helsinki. Written informed consent was required for participation. The patient population was enrolled between February 2007 and May 2009. The principal eligibility criterion was histologically confirmed pelvic CF-101 carcinoma scheduled to receive palliative radiation to 30 Gy in 3-Gy daily fractions. Other details on eligibility are given in the initial report. This phase 1 doseescalation study adopted a standard 3+3 expansion cohort design, where patients with advanced gastrointestinal carcinoma were enrolled onto four sequential dose levels of vorinostat, starting at 100 mg daily with dose escalation in increments of 100 mg. The primary objective was to determine tolerability of vorinostat, defined by dose-limiting toxicity and MTD, when administered concomitantly with palliative radiation to pelvic target volumes. Secondary objectives were to assess the biological activity of vorinostat, including the identification of possible biomarkers of HDAC inhibitor activity, and to monitor radiological response when given with pelvic radiotherapy. The study data on patient treatment tolerability, tumor histone acetylation following MCE Company 537034-15-4 vorinostat administration, and treatment-induced changes in tumor volume and apparent distribution coefficient, as assessed by magnetic resonance imaging, have been reported in detail previously. This analysis was performed by the Norwegian Genomics Consortium. Briefly, cRNA synthesis, amplification, and hybridization to Illumina Human WG-6 v3 Expression BeadChip arrays, containing 48,000 probes, were carried out as per manufacturer��s instructions. Signal intensities were extracted by the BeadArray Reader Software, and raw data were imported into the GenomeStudio v2010.1 Software, Gene Expression module v1.6.0. The primary array data are available in the Gene Expression Omnibus data repository. Analysis was performed using Bioconductor vR2.11.1 and the Bioconductor packages lumi 1.14.0, linear models for microarray data 3.4.4, and illuminaHumanv3BeadID.db 1.
